Robson, Mark <br/><br/>
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.  [electronic resource] 

 -  The New England journal of medicine  08 2017 
 - 523-533 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1533-4406 
<br/><br/><label>Standard No.: </label>10.1056/NEJMoa1706450  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant<br/>Disease-Free Survival<br/>Female<br/>Genes, BRCA1<br/>Genes, BRCA2<br/>Germ-Line Mutation<br/>Humans<br/>Kaplan-Meier Estimate<br/>Middle Aged<br/>Neoplasm Metastasis--drug therapy<br/>Phthalazines--adverse effects<br/>Piperazines--adverse effects<br/>Poly(ADP-ribose) Polymerase Inhibitors--adverse effects<br/>Receptor, ErbB-2<br/>Young Adult